Advances in Neovascular Retinal Diseases: The Expanding Role of the Optometrist is organized by Paradigm Medical Communications, LLC.,Release Date: September 16, 2022,Expiration Date: September 16, 2023,Program Overview:,Say goodbye to monthly anti-vascular endothelial growth factor (VEGF) injections for neovascular retinal diseases and hello to novel therapies that can extend treatment up to 4 to 6 months. These treatment advances are expected to expand the role of optometrists, who may now see such patients more frequently than retina specialists. Are you ready? Get all the breaking news in our fast-paced, news-style educational activity, as experts explain more durable therapies and what they mean for optometry practice.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Describe the natural history of neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) (with an emphasis on their insidious and progressive nature), which underscores the need for earlier diagnosis and treatment to prevent irreversible vision loss and complications,• Recognize signs of nAMD, DR, and diabetic macular edema (DME) that warrant referral to a retina specialist, based on accurate interpretation of examination and test findings,• Describe key characteristics of novel therapies that have been approved to treat neovascular retinal diseases,• Determine when patients who are receiving novel treatment for neovascular retinal diseases should return to the retina specialist based on clinical observation and the treatment being used.